rome and Heart-Valve-Diseases

rome has been researched along with Heart-Valve-Diseases* in 2 studies

Trials

1 trial(s) available for rome and Heart-Valve-Diseases

ArticleYear
Randomized trial of HTK versus warm blood cardioplegia for right ventricular protection in mitral surgery.
    Scandinavian cardiovascular journal : SCJ, 2013, Volume: 47, Issue:6

    To clarify the reliability of the one-shot histidine-tryptophane-ketoglutarate (HTK) cardioplegia for right ventricular (RV) myocardial protection during mitral surgery, in patients with or without pre-operative RV dysfunction.. Sixty patients undergoing isolated mitral surgery were randomized to myocardial protection with either one-shot HTK or intermittent warm blood cardioplegia (WBC). The RV function was assessed by echocardiography and hemodynamic assessment. Pre-operative tricuspid annular plane systolic excursion (TAPSE), an index of RV systolic function was used to dichotomize groups into patients having impaired (TAPSE < 15) or preserved (TAPSE ≥ 15) RV function.. There were no significant intergroup differences in the post-operative indexes of RV function in cases with TAPSE ≥ 15. In patients having TAPSE < 15 we observed statistically worse RV ejection fraction (RVEF, 15% ± 2% vs. 24% ± 3%), end-diastolic volume (RVEDV, 188 mL ± 20 vs. 179 mL ± 14) and fractional area change (RVFAC, 21% ± 6% vs. 30% ± 3%) after use of the HTK solution versus patients who received the WBC. These differences were associated with longer mechanical ventilation and ICU times in patients with impaired RV function and receiving HTK cardioplegia. In a substudy ten patients with TAPSE < 15 received intra-operative topical myocardial cooling in addition to HTK. The addition of topical cooling to HTK cardioplegia yielded statistically significant amelioration in post-operative RV function compared with patients who received the HTK solution without topical cooling (RVEF: 23% ± 3% vs. 15% ± 2%; RVEDV: 180 mL ± 9 vs. 188 mL ± 18; RVFAC: 8.5% ± 1% vs. 6% ± 2%).. The one shot HTK solution offers inferior RV protection compared with WBC, mainly in patients with depressed pre-operative RV function. When adopting HTK cardioplegia the addition of topical cooling is strongly advised.

    Topics: Aged; Cardiac Surgical Procedures; Cardioplegic Solutions; Female; Glucose; Heart Arrest, Induced; Heart Valve Diseases; Hemodynamics; Humans; Intensive Care Units; Length of Stay; Male; Mannitol; Middle Aged; Mitral Valve; Potassium Chloride; Procaine; Respiration, Artificial; Rome; Stroke Volume; Temperature; Time Factors; Treatment Outcome; Ventricular Dysfunction, Right; Ventricular Function, Right

2013

Other Studies

1 other study(ies) available for rome and Heart-Valve-Diseases

ArticleYear
The Ross procedure in patients aged less than 18 years: the midterm results.
    The Journal of thoracic and cardiovascular surgery, 2014, Volume: 147, Issue:1

    This study reviews a single-center experience with the Ross procedure in infants and young children.. From November 1993 to March 2012, 55 children aged less than 17 years underwent a Ross procedure. The patients ranged in age from 2 days to 17 years (median, 5.9 years). Thirteen patients were infants, and 18 patients were preschool children. The predominant indication for the Ross procedure was aortic stenosis. Twenty-seven patients (49%) with left ventricular outflow tract obstruction underwent a modified Ross-Konno procedure. Twenty-five patients (45%) had undergone 40 previous cardiac procedures. Preoperatively, 3 patients showed severe left ventricular dysfunction, with 2 of the patients requiring intubation and inotropic support. Concomitant procedures were performed in 11 patients (20%). Nine patients underwent mitral valve surgery, and 2 patients underwent subaortic membrane resection.. Patients were followed up for a median of 66 months (range, 3 months to 17 years). Overall survival at 1, 2, 5, and 10 years was 84.9%. Hospital mortality rate was 13% (7/55 patients). All deaths occurred in neonates or infants, except 1 who was aged less than 4 years. Freedom from reoperation for autograft failure was 100% at 1 year, 96.7% at 5 years, and 73.7% at 10 years. During follow-up, 7 patients required a reoperation on the autograft for dilatation and severe aortic insufficiency. Freedom from reoperation for the right ventricular outflow tract replacement was 56.1% at 10 years.. The low rate of autograft failure demonstrates that the Ross procedure is an attractive option for the management of aortic valve disease and complex left ventricular outflow tract obstruction in the pediatric population. However, alternative options must be considered in adolescents and young adults.

    Topics: Adolescent; Aortic Valve; Aortic Valve Stenosis; Blood Vessel Prosthesis Implantation; Chi-Square Distribution; Child; Child, Preschool; Female; Graft Survival; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Hospital Mortality; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; Male; Multivariate Analysis; Patient Selection; Postoperative Complications; Proportional Hazards Models; Pulmonary Artery; Pulmonary Valve; Reoperation; Risk Factors; Rome; Time Factors; Treatment Outcome; Ventricular Outflow Obstruction

2014